Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sepia esculenta bone refers to the dried internal shell (cuttlebone) of the golden cuttlefish Sepia esculenta. It is primarily composed of calcium carbonate and small amounts of organic matter such as β-chitin and proteins. Traditionally used in Chinese medicine as an antacid and for various gastric diseases, it has also been studied for its phosphate-binding properties in patients with chronic kidney disease. Cuttlebone can lower serum phosphate levels due to its high calcium content and may have additional effects from magnesium and iron components that block phosphorus absorption. Bioactive peptides derived from Sepia esculenta have demonstrated antioxidant activity in preclinical models[5][6]. The product is considered a natural substance rather than a conventional pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sepia esculenta bone.